Activated Vitamin B12, also known as holotranscobalamin (holo-TC), is a significant biomarker for Vitamin B12 status in the body. Unlike total B12, which measures both active and inactive forms, holo-TC specifically indicates the amount of Vitamin B12 that is available for cellular uptake and use. This makes it a more precise marker for assessing B12 deficiency, especially in clinical situations where accurate diagnosis is crucial. Holo-TC is particularly useful because it correlates well with intracellular erythrocyte B12 levels, providing a clearer picture of B12 availability at the cellular level. This biomarker is crucial for diagnosing and monitoring conditions related to Vitamin B12 deficiency, such as neurological disorders and certain types of anemia. The method commonly used for measuring holo-TC is flow cytometry.

Gastrointestinal microfilaments of the Actomyosin Network are critical for apical junctional complex biogenesis and function. The apical junctional complex, made up in part by tight junction proteins zonulin and occludin, is responsible for preventing antigen invasion and preservation of the biochemical homeostasis within the gastrointestinal tract. The Actomyosin Network can signal tight junction contractions and give structure to their assembly. Serum Antibodies Appear: → Autoimmune liver disorders → Celiac disease → Chronic hepatitis → Crohn’s disease → Myasthenia Gravis References: Clemente, et al. Enterocyte actin autoantibody detection: a new diagnostic tool in celiac disease, resulst of a multi-center study. Gastroenterol, 2004; 99:1551-1556. Gröschel-Stewart and Doniach. Immunological evidence for human myosin isoenzymes. Immunology, 1969; 17:991-994. Ivanov, et al. Differential roles for actin polymerization and a myosin II motor in assembly of the epithelial apical junctional complex. Mol Biol Cell, 2005; 16:2636-2650. Magalhaes, et al. Studies on the nature and significance of connective tissue antibodies in adult coeliac disease and Crohn’s disease. Gut, 1974; 15:284-288. 5. Romi, et al. Striational antibodies in Myasthenia Gravis: reactivity and possible clinical significance. Arch Neurol, 2005; 62:442-446.

Acylcarnitine is a crucial molecule in the body, playing a significant role in the metabolism of fatty acids. Essentially, it acts as a transporter that helps move fatty acids into the mitochondria, the energy powerhouses of our cells, where they can be broken down and used for energy production. The process begins when fatty acids bind to carnitine, forming acylcarnitine, which can then cross the mitochondrial membrane. Once inside the mitochondria, the fatty acids are released from carnitine and undergo a process called beta-oxidation, which ultimately generates ATP, the energy currency of cells. Measuring levels of acylcarnitines in the blood can provide valuable insights into metabolic health. Abnormal levels may indicate metabolic disorders such as fatty acid oxidation defects, which can lead to energy production issues and accumulation of toxic substances in the body. Therefore, understanding and monitoring acylcarnitine levels is important for diagnosing and managing various metabolic conditions.

What is Adenosine Deaminase (ADA)? Adenosine Deaminase (ADA) is an enzyme that plays a vital role in the breakdown of adenosine, a building block of DNA and RNA. This enzyme is essential for the proper development and function of the immune system, especially for T lymphocytes (T cells), which are white blood cells that help the body fight infections and diseases. Without sufficient ADA activity, toxic byproducts can accumulate and disrupt immune function. What does the “RBC” in the test name mean? The term RBC stands for Red Blood Cells. Measuring ADA specifically in red blood cells (as opposed to serum or other compartments) provides insight into how this enzyme is functioning within blood cell metabolism and may reflect longer-term or intracellular changes related to immune or hematologic conditions. Why is this test done? The Adenosine Deaminase, RBC test is used to evaluate conditions that affect immune function, red blood cell health, or chronic infections. Elevated or decreased ADA activity in RBCs may be associated with: Tuberculosis (TB) ADA levels are often elevated in TB, especially in pleural TB. While ADA in pleural fluid is more specific for TB diagnosis, ADA in RBCs may still support broader immune or infectious disease evaluations. Autoimmune or chronic inflammatory conditions Conditions like rheumatoid arthritis, lupus, or sarcoidosis may affect ADA levels due to chronic immune activation. Severe Combined Immunodeficiency (SCID) In rare cases, very low ADA activity may suggest a genetic ADA deficiency, a cause of SCID—a life-threatening immune disorder found in newborns. Leukemias and lymphomas Certain blood cancers may show abnormal ADA activity due to disrupted cell turnover and immune dysregulation. What does an elevated ADA in RBCs mean? An elevated Adenosine Deaminase (RBC) level may indicate: Increased T-cell activity or immune system stimulation Chronic infections, such as tuberculosis Autoimmune diseases (e.g., systemic lupus erythematosus or rheumatoid arthritis) Certain hematologic cancers (e.g., lymphoma or leukemia) Liver disease or other inflammatory states However, this marker is not disease-specific—an elevated result is a clue rather than a definitive diagnosis. What does a decreased ADA in RBCs mean? A low ADA level in red blood cells may suggest: ADA deficiency, a rare genetic disorder that leads to Severe Combined Immunodeficiency (SCID) in infants Impaired T-cell function, possibly from bone marrow suppression or immunosuppressive therapies Nutritional deficiencies affecting enzyme function In adults, mildly decreased levels are less common and may be of uncertain significance unless correlated with other findings. Here is a table summarizing the main conditions associated with abnormal Adenosine Deaminase (ADA) activity in red blood cells (RBCs): Condition ADA in RBCs Clinical Relevance Severe Combined Immunodeficiency (SCID) Decreased ADA deficiency is a genetic cause of SCID, leading to impaired lymphocyte development and function12345810. Diamond-Blackfan Anemia (DBA) Increased Elevated erythrocyte ADA is a supportive diagnostic marker for DBA, a congenital red cell aplasia7. Tuberculosis (especially pleural TB) Increased ADA is often elevated in TB, reflecting immune activation; more commonly measured in pleural fluid6. Autoimmune/Chronic Inflammatory Diseases Increased Conditions like lupus or rheumatoid arthritis can increase ADA due to chronic immune stimulation6. Hematologic Malignancies (Leukemia/Lymphoma) Increased Abnormal ADA activity may be seen due to disrupted cell turnover and immune dysregulation6. Bone Marrow Failure Syndromes (non-DBA) Variable Some inherited and acquired marrow failure syndromes may alter ADA, but less specifically than DBA7. Liver Diseases (e.g., hepatitis) Increased ADA may be elevated in various liver diseases due to inflammation or infection6. Nutritional Deficiencies Decreased Can impair enzyme function, leading to reduced ADA activity6. Note: ADA activity in RBCs is a supportive, not definitive, marker for these conditions. Results must always be interpreted in clinical context. How is this test used clinically? Physicians may order ADA in RBCs as part of a workup for: Chronic unexplained fatigue, fever, or weight loss Suspected tuberculosis (in combination with other TB-specific tests) Evaluation of immune deficiency or autoimmunity Monitoring of certain cancer types or treatments Investigation of abnormal red blood cell function Because ADA levels can be influenced by many different factors, this test is typically interpreted alongside other lab results and clinical findings. Key Takeaways Adenosine Deaminase, RBC helps assess immune activity and certain metabolic or infectious conditions. Elevated levels suggest immune activation, chronic inflammation, or infection. Low levels may indicate immune deficiency, including rare conditions like ADA-SCID. It’s a supportive test, not a standalone diagnostic tool—interpretation depends on clinical context. If you’ve received abnormal results for this test, speak with your healthcare provider to discuss what it may mean for your health and whether further testing is recommended.